HB1011
/ Hiera Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 07, 2026
HEART-1: A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: HieraBio Inc.
New P1 trial • Cardiomyopathy • Cardiovascular
1 to 1
Of
1
Go to page
1